LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

Search

Abbott Laboratories

Geschlossen

BrancheGesundheitswesen

127.4 -0.37

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

126.51

Max

129.49

Schlüsselkennzahlen

By Trading Economics

Einkommen

-135M

1.6B

Verkäufe

227M

11B

KGV

Branchendurchschnitt

16.335

106.172

EPS

1.3

Dividendenrendite

1.81

Gewinnspanne

14.46

Angestellte

114,000

EBITDA

-824M

2.2B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+14.93% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.81%

2.31%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.3B

226B

Vorheriger Eröffnungskurs

127.77

Vorheriger Schlusskurs

127.4

Nachrichtenstimmung

By Acuity

26%

74%

50 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Abbott Laboratories Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Nov. 2025, 13:14 UTC

Akquisitionen, Fusionen, Übernahmen

Correction to Abbott to Acquire Exact Sciences for $21 Billion Article

20. Nov. 2025, 13:11 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21 Billion -- Update

20. Nov. 2025, 12:55 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21 Billion

20. Nov. 2025, 21:23 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20. Nov. 2025, 16:51 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion -- Barrons.com

20. Nov. 2025, 15:08 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21 Billion -- 4th Update

20. Nov. 2025, 14:39 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Abbott and Exact Sciences Should Make a Good Fit -- Market Talk

20. Nov. 2025, 14:30 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk

20. Nov. 2025, 13:54 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Palo Alto Networks, Alphabet, and More -- Barrons.com

20. Nov. 2025, 13:51 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21 Billion -- 3rd Update

20. Nov. 2025, 13:25 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21 Billion -- 2nd Update

20. Nov. 2025, 13:24 UTC

Akquisitionen, Fusionen, Übernahmen

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20. Nov. 2025, 12:59 UTC

Akquisitionen, Fusionen, Übernahmen

Correction to Abbott to Acquire Exact Sciences for $21B Article

20. Nov. 2025, 12:58 UTC

Akquisitionen, Fusionen, Übernahmen

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20. Nov. 2025, 12:56 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21B -- Update

20. Nov. 2025, 12:54 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Labs: Expect to Maintain Investment-Grade Credit Rating >ABT EXAS

20. Nov. 2025, 12:53 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Labs to Fund Exact Sciences Deal With Cash on Hand, Debt Financing >ABT EXAS

20. Nov. 2025, 12:53 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Labs Sees Exact Sciences Deal Adding to Adjusted EPS in 2028, Beyond >ABT EXAS

20. Nov. 2025, 12:53 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Labs Sees Exact Sciences Deal Cutting Adjusted EPS by 20c in 2026, 16c in 2027 >ABT EXAS

20. Nov. 2025, 12:52 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Labs Sees at Least $100 Million Annual Pretax Synergies From Exact Sciences Deal by 2028 >ABT EXAS

20. Nov. 2025, 12:46 UTC

Akquisitionen, Fusionen, Übernahmen

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20. Nov. 2025, 12:40 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21B

20. Nov. 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Labs: Exact Sciences Deal Has Enterprise Value of About $23 Billion >ABT EXAS

20. Nov. 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

Exact Sciences to Be Acquired for $105/Share; Closed Wednesday at $86.18 >ABT EXAS

20. Nov. 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Labs Sees Acquisition Immediately Adding to Revenue Growth, Gross Margin >ABT EXAS

20. Nov. 2025, 12:31 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Labs: Exact Sciences Deal Has Total Equity Value of About $21 Billion >ABT EXAS

20. Nov. 2025, 12:30 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Buy Exact Sciences for $105/Share >ABT EXAS

20. Nov. 2025, 12:30 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott To Acquire Exact Sciences, A Leader In Large And Fast-growing Cancer Screening And Precision Oncology Diagnostics Segments >ABT

19. Nov. 2025, 21:27 UTC

Akquisitionen, Fusionen, Übernahmen

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

30. Okt. 2025, 12:38 UTC

Ergebnisse

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

Peer-Vergleich

Kursveränderung

Abbott Laboratories Prognose

Kursziel

By TipRanks

14.93% Vorteil

12-Monats-Prognose

Durchschnitt 147.24 USD  14.93%

Hoch 162 USD

Tief 136 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Abbott Laboratories – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

17

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

132.82 / 134.43Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

50 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat